NFKB1 and plasma cell myeloma: However, the NF-κB activity (at least in multiple myeloma cells) is mediated via two distinct pathways, canonical and non-canonical, which show opposing activity after bortezomib treatment, and full knowledge of the NF-κB regulation is not complete yet [45].